Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 5:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Spray Clear all
Completed Phase 2 Interventional Results available

Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Seasonal Allergic Rhinitis

NCT01277341
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Bepotastine Besilate Nasal Spray 2% Twice a day, Bepotastine Besilate Nasal Spray 3% Twice a day, Bepotastine Besilate Nasal Spray 4% Twice a day, Placebo Nasal Spray
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
12 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Sep 4, 2026, 5:44 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety of Gebauer's Pain Ease and Gebauer's Ethyl Chloride

NCT04207710
View directory record Official record
Conditions
Spray, Pain, Safety Issues
Interventions
Gebauer's Pain Ease Top Aerosol Mist Spray, Gebauer's Ethyl Chloride
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
Not listed
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Sep 4, 2026, 5:44 AM EDT
Terminated Not applicable Interventional Results available

Spray Cryotherapy for Esophageal Cancer (ICE-CANCER)

NCT01868139
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Liquid nitrogen spray cryotherapy with the truFreeze device
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 6, 2022 · Synced Sep 4, 2026, 5:44 AM EDT
Completed Phase 2 Interventional Results available

DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis

NCT02070965
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
DFD01 Spray, Comp01 Lotion
Drug
Lead sponsor
Primus Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
12
States / cities
Encinitas, California • Encino, California • Santa Rosa, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Sep 4, 2026, 5:44 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pain Study to Assess Local Anesthetic Efficacy and Safety of CTY-5339 on Gingival Mucosal Tissue in Normal Volunteers

NCT03233737
View directory record Official record
Conditions
No Disease State or Condition
Interventions
One spray CTY-5339-A, One spray CTY-5339-CB, One spray CTY-5339-P
Combination Product · Device
Lead sponsor
Cetylite Industries
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Sep 4, 2026, 5:44 AM EDT
Recruiting Phase 2 Interventional

Spray Cryotherapy for the Management of Benign Central Airway Stenosis (Cryo-BAS)

NCT06761170
View directory record Official record
Conditions
Stenosis of Trachea
Interventions
Spray cryo therapy, Standard of Care (SOC)
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Sep 4, 2026, 5:44 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia

NCT01357356
View directory record Official record
Conditions
Nocturia
Interventions
SER120 (750 ng/day), SER120 (1000 ng/day), SER120 (1500 ng/day), Placebo
Drug
Lead sponsor
Serenity Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New City, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Sep 4, 2026, 5:44 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)

NCT04408183
View directory record Official record
Conditions
SARS-CoV 2, Infection
Interventions
GLS-1200, Placebo
Drug
Lead sponsor
GeneOne Life Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
3
States / cities
Baton Rouge, Louisiana • Philadelphia, Pennsylvania • Conroe, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Sep 4, 2026, 5:44 AM EDT
Not listed Phase 3 Interventional

Efficacy of Promescent Lidocaine Spray in Men With Premature Ejaculation

NCT02241460
View directory record Official record
Conditions
Premature Ejaculation
Interventions
Placebo, Promescent Lidocaine Spray
Drug
Lead sponsor
Eugene Y Rhee, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Los Angeles, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Sep 4, 2026, 5:44 AM EDT
Terminated Phase 3 Interventional Results available

High Dose Oxytocin Nasal Spray for Treatment of Tinnitus

NCT04210310
View directory record Official record
Conditions
Tinnitus
Interventions
Oxytocin, Placebo nasal spray
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Sep 4, 2026, 5:44 AM EDT
Completed Phase 3 Interventional

To Assess the Safety and Efficacy of Ciclesonide Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis (BY9010/M1-402)

NCT00659750
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Ciclesonide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
23
States / cities
Encinitas, California • Long Beach, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Sep 4, 2026, 5:44 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine

NCT03488563
View directory record Official record
Conditions
Migraine
Interventions
B244, Vehicle
Biological
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
313 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
22
States / cities
Little Rock, Arkansas • Long Beach, California • Riverside, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Sep 4, 2026, 5:44 AM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)

NCT00163514
View directory record Official record
Conditions
Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
Interventions
Ciclesonide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 11 Years
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
58
States / cities
Oxford, Alabama • Huntington Beach, California • Mission Viejo, California + 52 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Sep 4, 2026, 5:44 AM EDT
Terminated Phase 2 Interventional Results available

An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray.

NCT02316847
View directory record Official record
Conditions
Epilepsy
Interventions
diazepam nasal spray
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
12 Years to 65 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
33
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2018 · Synced Sep 4, 2026, 5:44 AM EDT
Recruiting Phase 2 Interventional

The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients)

NCT05763953
View directory record Official record
Conditions
Paroxysmal Supraventricular Tachycardia
Interventions
Etripamil NS
Drug
Lead sponsor
Milestone Pharmaceuticals Inc.
Other
Eligibility
6 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Phoenix, Arizona • Oak Lawn, Illinois • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 4, 2026, 5:44 AM EDT
Completed Phase 2 Interventional Results available

A Prospective Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure

NCT02998840
View directory record Official record
Conditions
Prehypertension, Hypertension, Stage I
Interventions
B244, Vehicle
Biological
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tustin, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Sep 4, 2026, 5:44 AM EDT
Completed Phase 3 Interventional

Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia

NCT04952610
View directory record Official record
Conditions
Paroxysmal Supraventricular Tachycardia
Interventions
Etripamil NS 70 mg, Aptar Pharma Nasal Spray Bidose System
Drug · Device
Lead sponsor
Milestone Pharmaceuticals Inc.
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
17
States / cities
Little Rock, Arkansas • Vista, California • West Hills, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 4, 2026, 5:44 AM EDT
Terminated Phase 3 Interventional Results available

Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients

NCT02246920
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Fluticasone propionate, Flonase®, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
12 Years and older
Enrollment
1,474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Sep 4, 2026, 5:44 AM EDT
Completed Phase 2 Interventional Results available

Study of Buprenorphine Sublingual Spray Versus Standard of Care Narcotic Therapy for the Treatment of Post-Operative Pain

NCT03254459
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Buprenorphine Sublingual Spray, Morphine, Oxycodone Hydrochloride, Zofran
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
Pasadena, California • Murray, Utah
Source: ClinicalTrials.gov public record
Updated Oct 28, 2018 · Synced Sep 4, 2026, 5:44 AM EDT
Recruiting Phase 1Phase 2 Interventional

Evaluation of ELU42 Topical Spray for the Treatment of Diabetic Foot Ulcers

NCT07396376
View directory record Official record
Conditions
Diabetic Foot Ulcer, Wagner Grade 1 - 2, Chronic Wound, Open Wound
Interventions
ELU42 Topical Spray
Drug
Lead sponsor
Eluciderm Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
O'Fallon, Illinois • Springfield, Illinois • Oradell, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 4, 2026, 5:44 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Skin Sterility After Ethyl-Chloride Spray

NCT01292850
View directory record Official record
Conditions
Skin Sterility After Use of Ethyl-chloride Spray.
Interventions
Not listed
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 9, 2011 · Synced Sep 4, 2026, 5:44 AM EDT
Completed Phase 4 Interventional Results available

Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)

NCT00458835
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Ciclesonide
Drug
Lead sponsor
Covis Pharma S.à.r.l.
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Sep 4, 2026, 5:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating Relative Bioavailability of OC-01 (Varenicline) Nasal Spray as Compared to Orally Administered Varenicline

NCT04072146
View directory record Official record
Conditions
Healthy Subjects
Interventions
Vaenicline oral tablet 1 mg, then OC-01 (varenicline solution) nasal spray 0.12 mg, OC-01 (varenicline solution) nasal spray 0.12 mg then Varenicline oral tablet 1 mg
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 22, 2022 · Synced Sep 4, 2026, 5:44 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety & Effectiveness of a Nasal Spray to Treat Seasonal Allergies

NCT00719862
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Placebo nasal spray, 0.15% azelastine hydrochloride Nasal Spray
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older · Female only
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
34
States / cities
Huntington Beach, California • Long Beach, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2010 · Synced Sep 4, 2026, 5:44 AM EDT